Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is an open, single-arm, multicenter phase II study to investigate the efficacy and
safety of SG001 for relapsed or metastatic uterine cervical cancer patients with PD-L1
positive (CPS≧1), and has failed at least first line platinum-based chemotherapy.